



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q84960

Rian VAN MEETEREN, et al.

Appln. No.: 10/517,137

Group Art Unit: 1614

Confirmation No.: 6831

Examiner: Leslie A. Royds

Filed: August 17, 2005

For:

OVERACTIVE BLADDER TREATING DRUG

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed after the later of three months from the application's filing date and the mailing date of the first Office Action on the merits, but before a Final Office Action, Notice of Allowance, or an action that otherwise closes

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: 10/517,137

Attorney Docket No.: Q84960

prosecution in the application (whichever is earlier), and therefore Applicant is filing

concurrently herewith a Statement Under 37 C.F.R. § 1.97(e). No fee under 37 C.F.R. § 1.17(p)

is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

foreign language documents, Applicant encloses herewith a copy of a Communication from a

foreign patent office in a counterpart application citing such documents, together with an

English-language version (if not already included) of at least that portion of the Communication

indicating the degree of relevance found by the foreign patent office.

In addition, note that EP 1 203 582 A1 is the European counterpart of CN 1346268.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 30,951

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

CUSTOMER NUMBER

Date: May 23, 2006

2



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q84960

Rian VAN MEETEREN, et al.

Appln. No.: 10/517,137

Group Art Unit: 1614

Confirmation No.: 6831

Examiner: Leslie A. Royds

Filed: August 17, 2005

For:

OVERACTIVE BLADDER TREATING DRUG

STATEMENT UNDER 37 C.F.R. § 1.97(e)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The undersigned hereby states, upon information and belief:

That each item of information contained in the Information Disclosure Statement filed concurrently herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of said Information Disclosure Statement.

Respectfully submitted,

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373
CUSTOMER NUMBER

Date: May 23, 2006

Susan J. Mack

Registration No. 30,951

Substitute for Form 1449 A & B/PTO			(PI		Complete if Known		
			OTP	400	pplication Number	10/517,137	
INFOI	MATION !	חופכו הפ	STIDIE	8	on firmation Number	6831	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT MAY 2 9				3 5000 E	iling Date	August 17, 2005	
<u>51A1</u>	EMENI BY	APPLIC	AINI MAY	E	t Named Inventor	Rian VAN MEETEREN	
(use as many sheets as necessary)				- I	t Unit	1614	
			(V) CONTRACTOR	DEN E	xaminer Name	Leslie A. Royds	
Sheet	1	of	1		ttorney Docket Number	Q84960	

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Document Number		Publication Date			
		Number	Kind Code ² (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
		US					
		US					
		US					
		US					
		US					
		US					
		US					
		US					
		US					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date	Name of Patentee or		
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶	
		CN	1346268	Α	04-24-2002	Yamanouchi Pharmaceutical Co., Ltd.		
		EP	1 203 582	Al	05-08-2005	Yamanouchi Pharmaceutical Co., Ltd.	·	
		1						
		<u></u>		ļ				
					ļ			
							1	
					<u> </u>			

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.					
		Donna SELLERS, et al., Potential therapeutic targets for treatment of the overactive bladder, World J Urol, 2001, pp. 307-308, Vol. 19.					
		Yuan NING, New Drug Tolterodine For Treating Overactive Bladder, Pharmacology Development, 2001, pp. 52-56, Vol. 25,.					
<u> </u>							

<u> </u>	T		
		İ	
Examiner Signature		Date Considered	
			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.